S'abonner

A Pragmatic Study of Cardiovascular Disease During Long-Term COVID-19 - 04/05/24

Doi : 10.1016/j.amjmed.2024.03.011 
James F. Howick, MD a, , Petar Saric, MD, PharmD b, Mohamed Elwazir, MB, ChB b, Darrell B. Newman, MD b, Patricia A. Pellikka, MD b, Annelise S. Howick, BA c, John C. O'Horo, MD, MPH d, e, Leslie T. Cooper, MD f, Abhishek J. Deshmukh, MBBS b, Ravindra Ganesh, MBBS, MD g, Ryan Hurt, MD, PhD g, Bernard Gersh, MB, ChB, DPhil, FRCP, MACC b, John P. Bois, MD b, h
a Department of Internal Medicine 
b Department of Cardiovascular Medicine 
c Department of Emergency Medicine 
d Division of Public Health, Infectious Diseases and Occupational Medicine 
e Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, Minn 
f Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Fla 
g Division of General Internal Medicine 
h Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minn 

Requests for reprints should be addressed to James F. Howick V, MD, Department of Internal Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905.Department of Internal MedicineMayo Clinic200 1st St SWRochesterMN55905

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Saturday 04 May 2024

Abstract

Background

Many patients diagnosed with COVID-19 have persistent cardiovascular symptoms, but whether this represents a true cardiac process is unclear. This study assessed whether symptoms associated with long COVID among patients referred for cardiovascular evaluation are associated with objective abnormalities on cardiac testing to explain their clinical presentation.

Methods

A retrospective cohort study of 40,462 unique patients diagnosed with COVID-19 at our tertiary referral was conducted and identified 363 patients with persistent cardiovascular symptoms a minimum of 4 weeks after polymerase chain reaction confirmed COVID-19 infection. Patients had no cardiovascular symptoms prior to COVID-19 infection. Each patient was referred for cardiovascular evaluation at a tertiary referral center. The incidence and etiology of abnormalities on cardiovascular testing among patients with long COVID symptoms are reported here. The cohort was subsequently divided into 3 categories based on the dominant circulating severe acute respiratory syndrome coronavirus 2 variant at the time of initial infection for further analysis.

Results

Among 40,462 unique patients diagnosed with COVID-19 at our tertiary referral center from April 2020 to March 2022, 363 (0.9%) patients with long COVID were evaluated by Cardiology for possible cardiac sequelae from COVID and formed the main study cohort. Of these, 229 (63%) were vaccinated and 47 (12.9%) had severe initial infection, receiving inpatient treatment for COVID prior to developing long COVID symptoms. Symptoms were associated with a cardiac cause in 85 (23.4%), of which 52 (14.3%) were attributed to COVID; 39 (10.7%) with new cardiac disease from COVID, and 13 (3.6%) to worsening of pre-existing cardiac disease after COVID infection. The median troponin change in 45 patients with troponin measurements within 4 weeks of acute infection was +4 ng/dL (9 to 13 ng/dL). Among the total cohort with long COVID, 83.7% were diagnosed during the pre-Delta phase, 13.2% during the Delta phase, and 3.1% during the Omicron phase of the pandemic. There were 6 cases of myocarditis, 11 rhythm disorders, 8 cases of pericarditis, 5 suspected cases of endothelial dysfunction, and 33 cases of autonomic dysfunction.

Conclusion

This pragmatic retrospective cohort study suggests that patients with long COVID referred for cardiovascular evaluation infrequently have new, objective cardiovascular disease to explain their clinical presentation. A multidisciplinary, patient-centered approach is warranted for symptom management along with conservative use of diagnostic testing.

Le texte complet de cet article est disponible en PDF.

Keywords : Cardiovascular disease, Long COVID, Pandemic


Plan


 Funding: None.
 Conflicts of Interest: None.
 Authorship: All authors had access to the data and a role in writing the manuscript. JFH: Writing – review & editing, original draft, Investigation, Formal analysis; PS: Writing – review & editing, Methodology, Investigation, Data curation; ME: Writing – review & editing, Methodology, Investigation, Formal analysis; DBN: Writing – review & editing, Supervision, Investigation, Conceptualization; PAP: Writing – review & editing, Supervision; ASH: Writing – review & editing, original draft, Investigation, Formal analysis; JCO: Writing – review & editing, Supervision, Data curation; LTC: Writing – review & editing, Supervision; AJD: Writing – review & editing; RG: Writing – review & editing, Supervision; RH: Writing – review & editing, Supervision; BG: Writing – review & editing, original draft, Supervision; JPB: Writing – review & editing, original draft, Supervision.


© 2024  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.